Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 16, 2020
Daily News
October 16, 2020
- FPMAJ Urges Drug Makers to Ensure Stable Supply of Newly Listed Products
October 16, 2020
- LDP’s Health Committee OKs Bill to Amend Immunization Act
October 16, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Chugai, Roche Discussing Japan Development of Regeneron's COVID-19 Antibody Cocktail
October 16, 2020
- Forxiga’s Heart Failure Use Up for PAFSC Discussion on October 29
October 16, 2020
- JPWA Raided Too over Big 4 Wholesalers’ Bid-Rigging Scandal
October 16, 2020
- Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- COVID-19 Affecting Reimbursement Fee Incentive for Biosimilars: JPA Exec
October 16, 2020
- Evaluating Vaccine Efficacy Will Be a Challenge for COVID-19 Vaccine Development in Japan: Developers
October 16, 2020
- Chugai Files 1st Oral SMA Treatment in Japan
October 16, 2020
- Otsuka Misses Primary Goal in PIII Guadecitabine Trials
October 16, 2020
- Astellas to Snap Up US Implantable Medical Devices Startup iota
October 16, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…